EARLIER IDENTIFICATION AND EARLY INTERVENTION FOR CHILDREN WHO ARE DEAF OR HARD OF HEARING
With
Professor Greg Leigh AO, Director
NextSense Institute, Australia &
Conjoint Professor, Macquarie School of Education
Macquarie University, Sydney
RESEARCHER PROFILE
Filmed in Sydney, Australia | June 2025
As Director of NextSense Institute, Professor Leigh is responsible for leading the not-for-profit organisation’s world-class research and education programs and facilities.
Professor Leigh held a variety of positions in the education of children who are deaf or hard of hearing before entering academia. He holds a degree in Special Education from Griffith University, a Master of Science (Speech and Hearing) from Washington University and a PhD in Special Education from Monash University. In 2001, he was made a Fellow of the Australian College of Educators and in 2014, he was invested as an Officer in the Order of Australia (AO) for distinguished services to the deaf and hard of hearing community.
He is a member of the Editorial Board of The Journal of Deaf Studies and Deaf Education and has researched widely on issues related to the early development and education of children who are deaf or hard of hearing.
A former National President of the Education Commission for the World Congress of the World Federation of the Deaf, Professor Leigh has also Chaired the International Steering Committees of both the Asia-Pacific Congress on Deafness (APCD) and the International Congress on Education of the Deaf (ICED).
He has served on several Australian Government consultative committees, including the New South Wales Ministerial Standing Committee on Hearing, the National Neonatal Hearing Screening Working Party, and the Key Scientists Committee of the Hearing Cooperative Research Centre.
For the last 19 years, Professor Leigh has chaired the Australasian Newborn Hearing Screening Committee.
In his spare time, Professor Leigh is an active member/supporter of the Sydney Swans Football Club, and he and his wife enjoy symphonic music. He is also actively involved in the work of the St Vincent de Paul Society as a volunteer for the Vinnie’s Van program.
Source: Supplied
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Nutraceutical and pharmacological intervention in neurological disorders
Dr Virginie Lam is a neuroscientist and cerebrovascular biologist with over 15 years of research experience, including more than seven years post-PhD. She co-leads the Neurovascular and Metabolic Diseases Laboratory at the Curtin Medical Research Institute and holds an affiliate appointment at the Perron Institute for Neurological and Translational Science. Her research focuses on the interface between neurovascular health, cognitive function, and therapeutic translation in neurodegenerative disorders.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.
